In a recent study published by Eyes On Eyecare, real-world data indicates that pegcetacoplan offers sustained visual acuity (VA) benefits over an 18-month period. The study, conducted with a broad patient cohort, shows promising outcomes for individuals treated with pegcetacoplan, highlighting its potential as a reliable treatment for retinal conditions requiring long-term management. Notably, the continuous VA improvements observed underscore pegcetacoplan’s efficacy beyond clinical trials, providing valuable real-world insights for ophthalmologists and patients. The findings suggest that despite varied patient backgrounds and severity of ocular conditions, pegcetacoplan consistently enhances patient outcomes. As more real-world evidence surfaces, the ophthalmology community is optimistic about incorporating such treatments into routine care. This comprehensive data supports pegcetacoplan’s role in optimizing vision care and improving quality of life for patients with retinal medical needs. With visual health remaining a priority for many, these findings could influence future treatment protocols and patient management strategies.
Eyes On EyecareNew data shows NSW Land Clearing Rates Remain High Despite Reduction Promises
July 21, 2026
Recent data published on July 21, 2026, reveals that land clearing rates in New South Wales (NSW) remain worryingly high, contradicting government pledges to address